.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Julphar
Dow
Medtronic
Harvard Business School
Deloitte
Teva
Moodys
Novartis
McKesson

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,011,020

« Back to Dashboard

Which drugs does patent 6,011,020 protect, and when does it expire?


Patent 6,011,020 protects MACUGEN and is included in one NDA.

This patent has three hundred and sixty-five patent family members in thirty-six countries.

Summary for Patent: 6,011,020

Title: Nucleic acid ligand complexes
Abstract:This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
Inventor(s): Gold; Larry (Boulder, CO), Schmidt; Paul G. (San Marino, CA), Janjic; Nebojsa (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Application Number:08/434,465
Patent Claim Types:
see list of patent claims
Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,011,020

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,699,843 Method for treatment of tumors using nucleic acid ligands to PDGF► Subscribe
5,780,228 High affinity nucleic acid ligands to lectins► Subscribe
5,723,594 High affinity PDGF nucleic acid ligands► Subscribe
6,114,120 Systematic evolution of ligands by exponential enrichment: tissue selex► Subscribe
6,716,580 Method for the automated generation of nucleic acid ligands► Subscribe
5,766,853 Method for identification of high affinity nucleic acid ligands to selectins► Subscribe
6,762,290 High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors► Subscribe
6,110,900 Nucleic acid ligands► Subscribe
5,635,615 High affinity HIV nucleocapsid nucleic acid ligands► Subscribe
5,962,219 Systematic evolution of ligands by exponential enrichment: chemi-selex► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,011,020

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2002508387► Subscribe
Canada2223275► Subscribe
Canada2360748► Subscribe
Canada2219807► Subscribe
Canada2221318► Subscribe
Canada2223078► Subscribe
Canada2223003► Subscribe
European Patent Office1100960► Subscribe
Israel98456► Subscribe
Israel112141► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Express Scripts
UBS
Cerilliant
Harvard Business School
Cipla
Chinese Patent Office
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot